Meeting
2011 ASCO Annual Meeting
Circulating levels of RANK/RANKL and OPG in patients with bone metastasis treated with zoledronic acid: A prospective study.
Authors
T. Ibrahim
Osteoncology Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy
T. Ibrahim , L. Mercatali , E. Sacanna , R. Ricci , E. Scarpi , P. Serra , F. Fabbri , C. Tison , D. Amadori
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Tumor/Cell Biology
Citation
J Clin Oncol 29: 2011 (suppl; abstr 10611)
Abstract #
10611
Poster Bd #
33D
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
RANKL circulating levels in the evaluation of bone response in breast cancer (BC) patients.
First Author: Toni Ibrahim
Poster
2012 Breast Cancer Symposium
Correlation of receptor activator of nuclear factor kappa b (RANK) expression in breast cancer (BC) at the time of diagnosis with recurrence-free survival (RFS) and risk of bone-dominant metastases (BDM) in the I-SPY 1 trial (CALGB 150007/150012; ACRIN 6657).
First Author: Jiali Li
Poster
2011 ASCO Annual Meeting
The ZOTECT study: Effect of intravenous zoledronic acid on bone metabolism in patients with metastatic bone disease in prostate cancer (PC) and breast cancer (BC).
First Author: P. Hadji
Poster
2022 ASCO Annual Meeting
A phase 3 study to determine the breast cancer risk reducing effect of denosumab in women carrying a germline BRCA1 mutation (BRCA-P Study).
First Author: Nizar Bhulani